We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Events

02 Jun 2026 - 04 Jun 2026
17 Jun 2026 - 19 Jun 2026

Rapid DNA Flow Technology Platform Detects Tick-Borne Bacterial Pathogens

By LabMedica International staff writers
Posted on 13 Nov 2019
Ticks are the most important vectors for infectious diseases in the northern hemisphere and second only after mosquitos worldwide. More...
As a result, there is an increasing public health interest in tick-borne pathogens.

Ticks can transmit diseases such as Lyme disease, human granulocytic anaplasmosis, and spotted fever rickettsioses, among others. Therefore, there is a growing need to develop better and faster diagnostic tools that can detect zoonotic human pathogens in clinical samples.

Medical Infectious Disease Scientists from Rutgers University (New Brunswick, NJ, USA) and their international colleagues collected samples from 212 patients who presented a broad range of clinical signs/symptoms consistent with multisystem disorders that could be suggestive of an infection caused by any of the pathogens included in the panel of the tick-borne bacteria flow chip (TBFC) kit. Human DNA was used to spike positive controls came from cerebrospinal fluid (CSF) or biopsies from patients who tested negative to the pathogens included in the testing of the TBFC kit.

The TBFC is intended for the simultaneous qualitative detection of DNA from seven different genera of tick-borne bacteria, Anaplasma, Ehrlichia, Borrelia, Bartonella, Coxiella, Rickettsia, and Francisella, using a multiplex PCR followed by reverse dot blot automatic hybridization into a macroarray CHIP based on DNA-Flow Technology (hybriSpot). The kit offers the amplification of bacterial DNA by two multiplex polymerase chain reactions (PCRs) containing all primers for the specific amplification of the seven bacteria genera and two sets of primers for the amplification of two internal controls.

The scientists reported that the sensitivity of the TBFC was tested for each pathogen independently in the presence of human DNA. Despite human co-infections with tick-borne pathogens being rare, one of the strengths of the TBFC is that it can detect them. To prove that the TBFC detects co-infections, they included positive controls (103–104 plasmid copy/genome equivalents, PC/GE) for each pathogen. The results confirmed that the TBFC could detect all the pathogens simultaneously without compromising its sensitivity.

The TBFC platform offers four significant advantages. First, it is rapid and automatized, significantly shortening the time for the diagnosis of tick-borne pathogens. The TBFC kit gives results in 3.5 hours, while the in-house PCR-reverse line blot takes 8.5 hours for one pathogen. Second, it allows the simultaneous detection of multiple pathogens, which represents an excellent advantage for diseases that display similar symptoms early on. Third, the TBFC can analyze a wide variety of clinical samples with high sensitivity and specificity. Fourth, it is a valuable alternative to serology for early diagnosis.

The authors concluded that the TBFC kit is a rapid and highly sensitive and specific diagnostic tool, capable of simultaneously screening multiple bacterial pathogens. The study was published on October 22, 2019 in the journal Vector-Borne and Zoonotic Diseases.

Related Links:
Rutgers University


Gold Member
Automatic Hematology Analyzer
CF9600
Online QC Software
Acusera 24•7
Automated Urinalysis Solution
UN-9000
All-in-One Molecular System
AIO M160
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Characterization of EV separated by distinct methods (Photo courtesy of Yuanyuan Liu, Yanbin Guo et al. Engineering, doi.org/10.1016/j.eng.2025.12.009)

Liquid Biopsy Biomarkers May Improve Childhood Epilepsy Diagnosis

Childhood epilepsy remains a major neurological disorder with unmet needs for accurate, non-invasive biomarkers, as conventional tests such as electroencephalography and neuroimaging can have limited sensitivity... Read more

Molecular Diagnostics

view channel
Image: NeoCircle Study Synopsis (George, A.M., Chen, Y., Gladchuk, S. et al. EMBO Molecular Medicine (2026). DOI: 10.1038/s44321-026-00447-z)

Ultrasensitive MRD Blood Test Detects Early Breast Cancer Recurrence

SAGA Diagnostics (Morrisville, NC, USA), a company specializing in tumor-informed, blood-based cancer detection and precision medicine, announced the publication of a new study evaluating its Pathlight... Read more

Pathology

view channel
Image: Immune-related signals in routine bone marrow biopsy slides could help predict multiple myeloma outcomes and support more personalized treatment strategies (image credit: Shutterstock)

AI Tool Extracts Immune Signals from Biopsy to Inform Myeloma Therapy

Multiple myeloma is a bone marrow malignancy in which patients can respond very differently to the same treatments, making initial therapy decisions difficult. Clinicians must choose among options such... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.